Last reviewed · How we verify
Nebivolol and Atenolol
Nebivolol and atenolol are beta-blockers that reduce heart rate and blood pressure by blocking beta-adrenergic receptors on the heart and blood vessels.
Nebivolol and atenolol are beta-blockers that reduce heart rate and blood pressure by blocking beta-adrenergic receptors on the heart and blood vessels. Used for Hypertension, Angina pectoris, Heart failure.
At a glance
| Generic name | Nebivolol and Atenolol |
|---|---|
| Sponsor | Mylan Bertek Pharmaceuticals |
| Drug class | Beta-blocker (beta-1 selective adrenergic antagonist) |
| Target | Beta-1 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Both drugs are beta-1 selective adrenergic antagonists that decrease cardiac contractility and heart rate, reducing myocardial oxygen demand and lowering blood pressure. Nebivolol has additional vasodilatory properties through nitric oxide release. These agents are used to manage hypertension and cardiovascular conditions by reducing sympathetic nervous system activity.
Approved indications
- Hypertension
- Angina pectoris
- Heart failure
- Post-myocardial infarction management
Common side effects
- Fatigue
- Dizziness
- Bradycardia
- Hypotension
- Dyspnea
- Headache
Key clinical trials
- Rate Control in Patients With Atrial Fibrillation (NA)
- N-of-1 for Beta-Blockers in Cardiac Amyloidosis (PHASE4)
- A Preliminary Study for INFORMED (PHASE4)
- TREatment With Beta-blockers After myOcardial Infarction withOut Reduced Ejection fracTion" (PHASE4)
- Pilot Deprescribing N-of-1 Trials for Beta-blockers in HFpEF (PHASE4)
- Impact of Beta-blockers on Physical Function in HFpEF (PHASE4)
- ACEI or ARB and COVID-19 Severity and Mortality in US Veterans
- A Study Examining the Effects of Nebivolol Compared to Atenolol on Endothelial Function (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nebivolol and Atenolol CI brief — competitive landscape report
- Nebivolol and Atenolol updates RSS · CI watch RSS
- Mylan Bertek Pharmaceuticals portfolio CI